The content is available as a PDF (298.7 KB).
Abbreviations used
- IL
interleukin
Footnotes
Supported in part by grants CA37161, CA28771 and CA23077 from the National Cancer Institute, National Institutes of Health, Bethesda, Md.
References
- Alexanian R, Barlogie B, Dixon D (1986) High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105:8 [DOI] [PubMed] [Google Scholar]
- Alexanian R, Barlogie B (1988) VCAD-VAD as initial chemotherapy for multiple myeloma. ASH Abstr
- Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353 [DOI] [PubMed] [Google Scholar]
- Barlogie B, Jagannath S, Yau J, Dicke KA (1989) Alexanian R: High-dose therapy for multiple myeloma. In: Barlogie B, Alexanian R (eds) Abstr, 2nd Int Workshop on Myeloma: Advances in biology and therapy, Houston, Tex.
- Barlogie B, Epstein J, Selvanayagam P, Alexanian R (1989b) Plasma cell myeloma — new biological insights and advances in therapy. Review article. Blood 73:865–879 [PubMed] [Google Scholar]
- Barlogie B, Velasquez W, Alexanian R, Cabinallas F (1990) Etopo-side, dexamethasone, cytosine-arabinoside and cis-platinum (EDAP) in VAD-refractory myeloma. J Clin Oncol (in press)
- Bataille R, Klein B, Jourdan M, Zhang X-G (1990) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. JCI (in press) [DOI] [PMC free article] [PubMed]
- Bergsagel DE, Sprague CC, Austin C, Griffith KM (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma IV: L-phenylalanine mustard. Cancer Chemother Rep 21:87, 1962 [PubMed] [Google Scholar]
- Biachi A, Omede P, Massaia M, Camponi A, Attisano C, Dianzani U, Boccadoro M, Pileria L (1989) Phenotypic and functional analysis of peripheral blood lymphocytes during alpha-2B interferon maintenance therapy in multiple myeloma. Int Conf Multiple Myeloma (biology, pathophysiology prognosis and treatment), June 1989, Bologna Italy
- Caligaris-Cappio F, Bergui L, Merico F, Putto P, Schema M, Riva M, Gaidano GL (1989) Interleukin-dependent growth and differentiation of multiple myeloma precursor cells in circulating blood. In: Barlogie B, Alexanian R (eds) Abstr, 2nd Int Workshop on Myeloma: Advances in biology and therapy, Houston, Tex.
- Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw R, Lansdorp AR, Di Guglielmo R (1989) Production of interleukin-1 by bone marrow myeloma cells: its role in the pathogenesis of lytic bone lesions. Blood (in press) [PubMed]
- Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein. Cancer Res 46:5125 [PubMed] [Google Scholar]
- Epstein J, Barlogie B (1989) P-glycoprotein expression in plasma cell myeloma is associated with resistance VAD. Blood (in press) [PubMed]
- Ernst T, Gaydor A, Ritz J, Shipp MA (1988) Identification of a second transforming gene,ras-n, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72:1163–1167 [PubMed] [Google Scholar]
- Garrett LR, Durie BGM, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR (1987) Production of the bone resorbing cytokine lymphotoxin by cultured human myeloma cells. N Engl J Med 317:526 [DOI] [PubMed] [Google Scholar]
- Gonzales M, Orfao A, Gascon A, Miguel JF (1989) Expression of activated and natural killer-associated antigens in multiple myeloma. Multiple Myeloma (biology, pathophysiology prognosis and treatment), June 1989, Bologna Italy
- Gore ME, Millan S, Viner C, Harding M, Raymond J, Nandi A, Judson I, Maitland J, Bell J, Millar B, Selby P, McElwain TJ (1989) Continuous infusion of vincristine and adriamycin with high-dose methylprednisolone (VAMP) followed by high-dose melphalan and autologous bone marrow transplantation in the treatment of myeloma. In: Barlogie B, Alexanian R (eds) 2nd Int Workshop on Myeloma: Advances in biology and therapy, Houston. Tex. (abstr), p 53
- Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83 [DOI] [PubMed] [Google Scholar]
- Kawano M, Yamamoto I, Iwato K, Tanaka H, Kideki A, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A (1989) Myeloma cells produce IL-1, having bone-resorbing activity. Blood (in press) [PubMed]
- Klein P, Bataille R (1989) Autocrine and paracrine myeloma cell growth factors. Workshop on Myeloma: Advances in biology and therapy, Houston, Tex.
- Mandelli F, Tribalto M, Avvisati G, Cantonetti M, Petrucci MT, Boccadoro M, Pileri A, Resengotti L, Lauta V, Dammacco F (1988) Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treat Rev 15 (suppl A):43 [DOI] [PubMed] [Google Scholar]
- Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johannson B, Strander H (1979) Interferon therapy in myelomatosis. Lancet 1:245 [DOI] [PubMed] [Google Scholar]
- Oken MM, Kyle RA, Greipp RP, Kay NE, Tsiatis A, O'Connell MJ (1988) Alternating cycles of VBMCP with interferon (rIFN-alpha 2) in the treatment of multiple myeloma. Proc Am Soc Clin Oncol 7:868A [Google Scholar]
- Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU (1986) Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67:275 [PubMed] [Google Scholar]
- Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter D, Alexanian R, Saunders G, Barlogie B (1988) Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71:30–35 [PubMed] [Google Scholar]
- Seremetis S, Inghirami G, Ferrero D, Newcomb E, Knowles D, Dotto G-P, Dalla-Favera R (1989) Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblast byras oncogene. Science 243:660–663 [DOI] [PubMed] [Google Scholar]
- Tsuchiya H, Epstein J, Selvanayagam P, Dedman J, Gallick G, Alexanian, Barlogie B (1988) Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood 72:796–800 [PubMed] [Google Scholar]